Monoclonal antibody: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
No edit summary
mNo edit summary
 
(2 intermediate revisions by one other user not shown)
Line 4: Line 4:
The [[World Health Organization]] is refining naming conventions for monoclonal antibodies. <ref name=WHOname>{{citation
The [[World Health Organization]] is refining naming conventions for monoclonal antibodies. <ref name=WHOname>{{citation
  | url = http://www.who.int/entity/medicines/publications/druginformation/issues/WHO-DI-22-2.pdf
  | url = http://www.who.int/entity/medicines/publications/druginformation/issues/WHO-DI-22-2.pdf
  | journal = WHO Drug Information
  | journal = WHO Drug Information  | volume= 22  | issue = 2  | year = 2008  | title = International Nonproprietary Names for monoclonal antibodies: IFPMA proposal  | author = Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse
  | volume= 22
  | issue = 2
  | year = 2008
  | title = International Nonproprietary Names for monoclonal antibodies: IFPMA proposal
  | author = Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse
from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group
from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group
}}, pp. 97-107</ref> Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.<ref name=IFPMA>{{citation
}}, pp. 97-107</ref> Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.<ref name=IFPMA>{{citation  | author =  International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group  | title = Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal
  | author =  International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group
antibodies  | year = 2008  | url = http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf}}</ref>
  | title = Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal
 
antibodies
Naming of monoclonal antibodies is governed by [[World Health Organization]]’s [http://www.who.int/medicines/services/inn/en/ International Nonproprietary Name] (INN):
  | year = 2008
* [[Human monoclonal antibody]]. INN names end in -umab. Example is [[olaratumab]].
  | url = http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf}}</ref>
* [[Humanized monoclonal antibody]]. INN names end in -zumab. Example is [[benralizumab]].
* [[Chimeric monoclonal antibody]]. INN names end in -ximab. Example is [[rituximab]].


==References==
==References==
{{reflist|2}}
{{reflist|2}}[[Category:Suggestion Bot Tag]]

Latest revision as of 06:00, 21 September 2024

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

A monoclonal antibody is an immune substance "produced by clones of cells such as those isolated after hybridization of activated B-lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas." [1] Monoclonal antibodies have extensive applications in clinical medicine and immunochemistry.

The World Health Organization is refining naming conventions for monoclonal antibodies. [2] Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.[3]

Naming of monoclonal antibodies is governed by World Health Organization’s International Nonproprietary Name (INN):

References

  1. Anonymous (2024), Antibody, monoclonal (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), "International Nonproprietary Names for monoclonal antibodies: IFPMA proposal", WHO Drug Information 22 (2), pp. 97-107
  3. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), [http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal antibodies]